Explore All 191 Merger Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | September 30, 2025 |
| Target | Clywedog Therapeutics |
| Sector | Life Science |
| Buyer(s) | Clywedog Therapeutics |
| Deal Type | Merger |
| Advisor(s) | Snell & Wilmer (Legal) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
| Employees | 105 |
| Revenue | 15M USD (2024) |
Clywedog Therapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies that guide T cells to overcome autoimmunity and inflammatory diseases. Clywedog Therapeutics was founded in 2016 and is based in Didcot, United Kingdom.
| Deal Context for Buyer | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science | 2 of 2 |
| Type: Merger | 1 of 1 |
| Country: United Kingdom | 1 of 1 |
| Year: 2025 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-13 |
Avidea Technologies
Baltimore, Maryland, United States Avidea Technologies is a biotechnology company that is advancing the next generation of safer and more effective T cell immunotherapies for treating cancer, infections, and autoimmune diseases. Avidea Technologies is based in Baltimore, Maryland. |
Buy | $40M |
